专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130122128A1 COMPOSITION COMPRISING AN EXTRACT OF HARDY KIWI FOR PREVENTING OR TREATING BALDNESS DISORDERS OR SEBORRHEIC SKIN DISORDERS 审中-公开
标题翻译：组合物包含用于预防或治疗嗜中性粒细胞性贫血或严重皮肤疾病的硬骨髓提取物
公开(公告)号：US20130122128A1
公开(公告)日：2013-05-16
申请号：US13719801
申请日：2012-12-19
申请人： VIROMED CO., LTD
发明人： Bongcheol KIM , Hwa-Jun LEE , Mirim JIN , Hyung-Jin JUNG , Sunyoung KIM
IPC分类号： A61K36/185
CPC分类号： A61K36/185 , A23L2/52 , A23L33/105 , A23V2002/00 , A61K8/0216 , A61K8/97 , A61K2800/91 , A61K2800/92 , A61Q5/006 , A61Q7/00 , A61Q19/00 , A61Q19/008 , A23V2200/318 , A23V2250/21
摘要： Provided is a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.
摘要翻译：提供粗提取物，非极性溶剂可溶性提取物或强力猕猴桃的纯化提取物用于制备用于治疗和预防人和哺乳动物的秃头症和脂溢性皮肤病的治疗剂，以及保健食品，食品添加剂，饲料添加剂，包含其的化妆品组合物。强力猕猴桃减少血液DHT水平，促进小鼠模型实验中发根的形成，抑制头发脱落，改善角质层皮脂，脂溢性皮炎等志愿者脂溢性皮肤病。

2. 发明申请

US20190085092A1 ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS 审中-公开
公开(公告)号：US20190085092A1
公开(公告)日：2019-03-21
申请号：US15755819
申请日：2016-08-30
申请人： bluebird bio, Inc. , ViroMed Co., LTD.
发明人： Richard MORGAN , Kevin FRIEDMAN , Seung Shin YU , Jae-Gyun JEONG , Jin-A CHAE
IPC分类号： C07K16/30 , C07K14/705 , A61P35/00
摘要： The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.

3. 发明申请

US20180222955A1 GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM 审中-公开
公开(公告)号：US20180222955A1
公开(公告)日：2018-08-09
申请号：US15942440
申请日：2018-03-31
申请人： VIROMED CO., LTD.
发明人： Jong Mook KIM , Jae Gyun JEONG
IPC分类号： C07K14/475 , A61K31/711 , A61K48/00 , A61K38/18
CPC分类号： C07K14/4753 , A61K31/711 , A61K38/1833 , A61K48/005
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

4. 发明授权

US09404090B2 Adenovirus producing novel cell line and the use thereof 有权
标题翻译：产生新型细胞系的腺病毒及其用途
公开(公告)号：US09404090B2
公开(公告)日：2016-08-02
申请号：US14360195
申请日：2012-11-22
申请人： VIROMED CO., LTD.
发明人： Seung Shin Yu , Chang-Wan Joo , Jin-A Chae , Yeon Suk Cha
IPC分类号： C12P21/00 , C12N15/86 , C12N7/00 , C12N5/16 , C12N15/12 , C12N15/13 , C12N5/10
CPC分类号： C12N7/00 , C12N15/86 , C12N2710/10351 , C12P21/00
摘要： The invention relates to a cell line in which an expression construct is introduced into genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus El coding gene sequence of SEQ ID NO: 32 operatively linked to the promoter. The cell line of the invention is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the invention shows superior adenovirus producing ability, as compared with an HEK 293 cell which is one of conventional adenovirus producing cell lines.
摘要翻译：本发明涉及其中将表达构建体引入基因组DNA的细胞系，该表达构建体包括：（a）可在动物细胞中可操作并且与腺病毒异源的启动子; 和（b）与启动子有效连接的SEQ ID NO：32的修饰的腺病毒E1编码基因序列。本发明的细胞系不太可能产生复制型腺病毒（RCA）。与常规细胞系相比，本发明的腺病毒产生细胞系与同源重组产生RCA的可能性低。因此，这可以在使用腺病毒的基因治疗期间调节所需量的病毒，并防止由腺病毒过量产生引起的组织损伤和毒性作用。此外，与作为常规腺病毒产生细胞系之一的HEK 293细胞相比，本发明的细胞系显示出优异的腺病毒产生能力。

5. 发明申请

US20140308704A1 ADENOVIRUS PRODUCING NOVEL CELL LINE AND THE USE THEREOF 有权
标题翻译： ADENOVIRUS生产新型细胞系及其用途
公开(公告)号：US20140308704A1
公开(公告)日：2014-10-16
申请号：US14360195
申请日：2012-11-22
申请人： VIROMED CO., LTD.
发明人： Seung Shin Yu , Chang-Wan Joo , Jin-A Chae , Yeon Suk Cha
IPC分类号： C12N7/00 , C12P21/00
CPC分类号： C12N7/00 , C12N15/86 , C12N2710/10351 , C12P21/00
摘要： The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the present invention shows superior adenovirus producing ability, as compared with an HEK293 cell which is one of conventional adenovirus producing cell lines. Thus, it is possible to produce a time and cost-saving replication incompetent adenovirus. Therefore, the cell line of the present invention effectively produces a replication incompetent adenovirus and provides a safe and effective dose of adenovirus during gene therapy.
摘要翻译：本发明涉及其中将表达构建体导入基因组DNA的细胞系，该表达构建体包括：（a）可在动物细胞中操作并与腺病毒异源的启动子; 和（b）与启动子可操作地连接的SEQ ID NO：1的修饰的腺病毒E1编码基因序列。根据本发明，本发明的细胞系是不太可能产生复制型腺病毒（RCA）的新型细胞系。与常规细胞系相比，本发明的腺病毒产生细胞系与同源重组产生RCA的可能性低。因此，这可以在使用腺病毒的基因治疗期间调节所需量的病毒，并防止由腺病毒过量产生引起的组织损伤和毒性作用。此外，与作为常规腺病毒产生细胞系之一的HEK293细胞相比，本发明的细胞系显示出优异的腺病毒产生能力。因此，可以产生时间和成本节省的复制无能力的腺病毒。因此，本发明的细胞系有效地产生复制无能的腺病毒，并且在基因治疗期间提供安全有效的腺病毒剂量。

6. 发明申请

US20190315872A1 ANTI-C-MET ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：US20190315872A1
公开(公告)日：2019-10-17
申请号：US16075304
申请日：2017-02-06
申请人： VIROMED CO., LTD.
发明人： Seung Shin YU , Jae-Gyun JEONG , Dongsik KIM , Juwon SHIM
IPC分类号： C07K16/28 , A61P13/12 , A61P17/02 , A61P25/28 , A61P9/10
摘要： The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.

7. 发明申请

US20190111154A1 TREATMENT OF NEUROPATHY WITH DNA CONSTRUCT EXPRESSING HGF ISOFORMS WITH REDUCED INTERFERENCE FROM GABAPENTINOIDS 审中-公开
公开(公告)号：US20190111154A1
公开(公告)日：2019-04-18
申请号：US16161101
申请日：2018-10-16
申请人： ViroMed Co., Ltd.
发明人： Sunyoung KIM , Junghun LEE
IPC分类号： A61K48/00 , C12N15/62 , A61P29/02 , A61K9/00 , A61P25/04 , A61P25/02
摘要： The present invention relates to methods of treating neuropathy patients who have been administered a gabapentinoid. In particular, the methods involve administering a nucleic acid construct encoding human HGF proteins after discontinuing gabapentinoid. The present invention provides a novel method for a specific patient population to achieve a better therapeutic outcome by avoiding interference of therapeutic effects by gabapentinoids.

8. 发明申请

US20170281729A1 COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL VASCULAR DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1A 审中-公开
公开(公告)号：US20170281729A1
公开(公告)日：2017-10-05
申请号：US15514244
申请日：2015-09-25
申请人： VIROMED CO., LTD.
发明人： Jae-Gyun JEONG , Jung Hun LEE , Nayeon LEE
IPC分类号： A61K38/19 , A61K48/00 , A61K38/18
CPC分类号： A61K38/195 , A61K38/18 , A61K38/1833 , A61K48/00 , A61K48/0016
摘要： The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1α (SDF-1α); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1α. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1α or a polynucleotide codes a protein thereof.

9. 发明授权

US10927177B2 Methods of treatment using anti-c-met antibodies 有权
公开(公告)号：US10927177B2
公开(公告)日：2021-02-23
申请号：US16075304
申请日：2017-02-06
申请人： VIROMED CO., LTD.
发明人： Seung Shin Yu , Jae-Gyun Jeong , Dongsik Kim , Juwon Shim
IPC分类号： A61K39/395 , A61P13/12 , A61P9/10 , A61P25/28 , A61P17/02 , C07K16/28 , C07K14/47 , C07K14/475 , A61K39/00
摘要： The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.

10. 发明申请

US20190241632A1 GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM 审中-公开
公开(公告)号：US20190241632A1
公开(公告)日：2019-08-08
申请号：US16387587
申请日：2019-04-18
申请人： ViroMed Co., Ltd.
发明人： Jong Mook KIM , Jae Gyun JEONG
IPC分类号： C07K14/475 , A61K31/711 , A61K48/00 , A61K38/18
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式